Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Testosterone Linked to Higher Rate of Colon Cancer in Males

By LabMedica International staff writers
Posted on 22 Dec 2014
Results of experiments carried out with two established animal colon cancer models indicated that the male hormone testosterone was responsible for males having a greater likelihood of developing the disease.

It has been recognized recently that men develop colonic adenomas and carcinomas at an earlier age and at a higher rate than women. More...
This sex susceptibility also occurs in the ApcPirc/+ (Pirc) rat model of early colonic cancer, with male Pirc rats developing twice as many adenomas as females. The ApcMin/+ mouse also shows enhanced male susceptibility to cancer formation, but only in the colon.

Investigators at the University of Missouri (Columbia, USA) worked with these two rodent populations to determine whether the males' natural high levels of testosterone or the lack of female hormones was related to the increased development of colon cancer.

They reported in the November 3, 2014, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS) that removing testosterone from the rodents by castration caused colon cancer rates to decrease dramatically. Restoration of testosterone by dietary supplementation restored the tendency for cancer development. In contrast, removal of the ovaries, which eliminated female hormones, did not cause an increase in rate of cancer development. Dietary supplementation of female hormones also failed to have any effect.

“Previously, scientists believed that female hormones may have lent some sort of protection against tumor susceptibility,” said first author Dr. James Amos-Landgraf, assistant professor of veterinary pathobiology at the University of Missouri. “However, by showing that removing testosterone from rats leads to a drastic decrease in colon cancer susceptibility, it appears that male hormones may actually contribute to colon tumor growth rather than female hormones being protective. All women have some level of testosterone in their bodies naturally, but those levels typically are much lower than estrogen and other female hormones. Once women experience menopause and their female hormone levels decrease, their testosterone levels become relatively higher. This corresponds to the time when they begin to experience higher rates of colon cancer and could be a sign of a relationship between testosterone levels and colon tumor growth.”

Related Links:

University of Missouri



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.